Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors must act before the December 15, 2025 deadline to serve as lead plaintiff, representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific claims include that Baxter was aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product recalls and halting new sales [5]. - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of Marex Group plc to secure legal counsel before the December 8, 2025 deadline for a securities class action lawsuit related to the company's misleading financial statements and practices [2][6]. Group 1: Class Action Details - The class action pertains to investors who purchased Marex securities between May 16, 2024, and August 5, 2025, and they may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][4]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 8, 2025 [4][6]. Group 2: Allegations Against Marex - The lawsuit alleges that Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements between subsidiaries and related parties [6]. - As a result of these actions, Marex's financial statements were deemed unreliable, and positive statements about the company's business and prospects were misleading [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of Nidec Corporation shareholders due to allegations of materially misleading business information issued by the company [2][3]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Nidec's stock price, which fell 22% following a report of accounting issues related to its management [4]. - Nidec's American Depositary Receipts (ADRs) experienced a decline of 22.7% on September 4, 2025, marking the largest one-day drop for the company [4]. Group 2: Class Action Information - Investors who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no upfront costs due to a contingency fee arrangement [3]. - Interested investors can join the prospective class action by submitting a form or contacting the law firm directly [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [5]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period, highlighting potential misstatements and misleading information from the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Telix Pharmaceuticals Ltd. securities purchased between February 21, 2025, and August 28, 2025 [1]. - The lawsuit alleges that defendants made materially false and misleading statements regarding the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by January 9, 2026, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a class action lawsuit related to securities purchased between July 26, 2024, and September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against DexCom - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which rendered them less reliable and posed health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues related to the adulterated devices [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must move the court by December 15, 2025 [4]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of its Novum IQ Large Volume Pump, which suffered systemic defects leading to serious patient risks [6]. Group 2: Allegations Against Baxter - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [6]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to continued harm [6]. - The allegations suggest that Baxter's statements about the product's safety, efficacy, and sales prospects were materially false and misleading, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors [5]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing shareholder interests [5].

New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for misrepresentations regarding the market demand and launch of its sleep apnea device, Inspire V, during the specified Class Period [2][6]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Inspire Medical common stock between August 6, 2024, and August 4, 2025 [2]. - Defendants allegedly made materially false and misleading statements about the demand for Inspire V and the company's readiness for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Investor Information - Investors who purchased Inspire Medical common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - To participate in the class action, investors must act before the deadline of January 5, 2026, to serve as lead plaintiff [4]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [5]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against MoonLake - The complaint alleges that during the class period, the defendants made false or misleading statements and failed to disclose material facts regarding the differences between Nanobodies and monoclonal antibodies [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's Nanobody structure does not provide superior clinical benefits compared to BIMZELX [5]. - The lawsuit asserts that when the true information became public, investors suffered damages due to the misleading statements made by the defendants [5].